Methods: A retrospective review of patients who received omalizumab therapy for a minimum of two years during 2004-2011. Visit compliance and response rates to therapy were evaluated at three time-periods: P1(16-wk), P2(1-yr) and P3(2-yr). Compliance was calculated by comparing number of recommended injections to injections actually received. Patients were grouped based on compliance rates: C1(<50%, non-compliant);C2(50-75%); C3(76%-89%) and C4(≥90%, high compliance). A positive response was identified by combination of complete control or marked improvement by Physician’s GETE (Global Evaluation of Treatment Effectiveness), AND improvement in asthma symptoms pre- and post-omalizumab therapy in three or more of the following six parameters: Decrease by ≥50% in asthma exacerbations (AE); steroid-bursts; ER-visits; hospitalizations; improvement in FEV1(≥200cc); increase in ACT score(≥3).
Results: Visit compliance and response rates were evaluated for 124 patients at P1, P2 and P3. Overall compliance: P1[98.4%]; P2[89.5%] and P3[87.1]. Overall response rate: P1[33.0%]; P2[62.9%] and P3[63.7%]. Responder-rate for C2[P2(70.0%);P3(71.0%)] and C3[P2(64.0%);P3(66.7%)] is higher than C4[P2(60.7%);P3(62.5%)]. Number of Patients with very high compliance (C4) drastically drops from P1 [89(72%)] to P2[56(45%)]. Response rates for C1 and C4 are not statistically different (p-value,0.257).
Conclusions: In this analysis, visit compliance does not statistically impact response rate to omalizumab therapy. Compliance to omalizumab therapy decreases over time. Higher compliance does not correspond to high response rate.